Table 1 Clinical characterization of the Pronmed cohort analyzed as the discovery set, and the Biobanque Québécoise de la COVID-19 (BQC19) cohort used for validation
Pronmed | BQC19 | |||
|---|---|---|---|---|
n | 165 | Missing (%) | 1052 | Missing (%) |
Women (%) | 42 (25.5) | 0 | 572 (54.4) | 0 |
Age (mean ± SD) | 63 ± 14 | 0 | 63 ± 20 | 2 (0.2) |
max eOSM (mean ± SD) | 318 ± 19 | 0 | 304 ± 16 | 0 |
Hospitalized (%) | 165 (100) | 0 | 885 (90.6) | 75 (7.1) |
ICU admission (%) | 165 (100) | 0 | 304 (34.7) | 9 (0.9) |
Invasive ventilation (%) | 126 (76.4) | 0 | 74 (7.2) | 21 (2.0) |
Acute kidney injury (%) | 106 (64.6) | 1 (0.6) | 238 (24.5) | 8 (0.8) |
Death (%) | 49 (29.9) | 1 (0.6) | 122 (12.6) | 81 (7.7) |
Long-COVID | ||||
|---|---|---|---|---|
n | 54 | Missing (%) | 615 | Missing (%) |
Time to Follow-up (median[IQR]) | 139 [123–181] | 0 | 101 [66–184] | 0 |
Physical (mean ± SD) | 0.28 ± 0.20 | 3 (5.5) | 0.24 ± 0.30 | 33 (5.4) |
Mental (mean ± SD) | 0.23 ± 0.16 | 10 (18) | 0.20 ± 0.22 | 16 (2.6) |